SEARCH

SEARCH BY CITATION

Keywords:

  • bulimia nervosa;
  • serotonin;
  • transporter;
  • positron emission tomography;
  • imaging;
  • midbrain

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Objective:

Physiological and pharmacological studies indicate that altered brain serotonin (5-HT) activity could contribute to a susceptibility to develop appetitive and behavioral alterations that are characteristic of bulimia nervosa (BN).

Method:

Eight individuals recovered from BN (REC BN) and eight healthy control women were scanned with [11C]DASB and positron emission tomography imaging of the 5-HT transporter (5-HTT). Logan graphical analysis was applied, and parametric binding potential (BPnondisplaceable (ND)) images were generated. Voxel-by-voxel t-tests and a region of interest (ROI) analysis were conducted.

Results:

REC BN had significantly lower [11C]DASB BPND in midbrain, superior and inferior cingulate and significantly higher [11C]DASB BPND in anterior cingulate and superior temporal gyrus in the voxel-based analysis. ROI analysis indicated lower [11C]DASB BPND in midbrain (p = .07), containing the dorsal raphe, in REC BN, consistent with our earlier studies.

Discussion:

These preliminary findings of a small-scale study confirm and extend previous data suggesting that ill and recovered BN have altered 5-HTT measures, which potentially contribute to BN symptomatology and/or differential responses to medication. © 2011 by Wiley Periodicals, Inc. (Int J Eat Disord 2012;)


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Bulimia nervosa (BN) is a disorder of unknown etiology that tends to have an onset during adolescence in women. It is characterized by restrictive eating alternating with binge eating and purging, as well as concomitant body image distortions. Most individuals maintain a normal body weight. BN is commonly associated with mood disturbances, obsessionality, and poor impulse control.1–3

Physiological and pharmacological data support the possibility that altered central nervous system serotonin (5-HT) neurotransmitter activity could contribute to a susceptibility to develop appetitive and behavioral alterations in BN.2, 4 Altered 5-HT activity in BN could be a consequence of pathological dietary behaviors that occur during the ill (symptomatic) state. However, people who have recovered (REC) from BN continue to have 5-HT alterations, as well as behavioral symptoms consistent with a dysregulation of 5-HT neuronal pathways,5, 6 raising the possibility that such alterations are trait-related and contribute to the pathogenesis of this disorder.

There has been much interest in determining whether individuals with BN have alterations of the 5-HT transporter (5-HTT). The 5-HTT is located presynaptically on the axon terminals of 5-HT neurons and on the cell bodies of serotonin neurons.7 A main function of the 5-HTT is to transport serotonin from the synapse back into the presynaptic neuron for storage and future release. This contributes to modulating 5-HT neurotransmission and intrasynaptic 5-HT availability. In fact, imaging studies have found reduced 5-HTT levels in symptomatic individuals who binge compared with controls. Tauscher et al.,8 using single-photon emission computed tomography (SPECT), found reduced [123I]β-CIT binding in the thalamus and striatum in 10 individuals who were ill with BN. Reduced [123I]β-CIT binding values in the brainstem have also been found using SPECT in participants ill with binge eating disorder.9 We previously evaluated midbrain (dorsal raphe), striatum, thalamus, and subgenual cingulate in subgroups of patients REC from eating disorders using positron emission tomography (PET) and [11C]McN5652, an older radioligand for the 5-HTT, and showed lower dorsal raphe values in REC BN than in control women (CW). MANOVA confirmed global group differences and univariate ANOVA confirmed group differences for dorsal raphe and antero-ventral striatum although individual group contrasts for CW versus REC BN did not reach statistical significance.10 In addition, Steiger et al.11 showed that individuals REC from BN have reduced platelet [3H]paroxetine binding when compared with CW.

This is the first study to use PET and [11C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile ([11C]DASB), a newer ligand, to investigate 5-HTT binding in REC BN individuals. [11C]DASB is superior to [123I]2 β-carbomethoxy-3 beta-(4-iodophenyl) tropane ([123I]β-CIT) or trans-1,2,3,5,6,10-β-hexahydro-6-[4-(methylthio)phenyl] pyrrolo-[2,1-a]-isoquinoline ([11C]McN5652) because of higher specific-to-nonspecific ratios.12 Previous data have shown that [11C]DASB can reliably assess 5-HTT binding in brain regions including the midbrain, thalamus, striatum, medial temporal lobe, and anterior cingulate, as described by Frankle et al.13 On the basis of previous findings, we predicted that REC BN would have diminished [11C]DASB BPND in midbrain and striatal regions compared to healthy CW.

Method

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Participants

Eight women who had REC from BN were compared to eight control women (CW). REC BN must have met a lifetime diagnosis of BN with no history of AN. The individuals were recruited as previously described for earlier independent samples.14, 15 All individuals, both REC BN and CW, underwent four levels of screening: (1) a brief phone screening, (2) an intensive screening assessing psychiatric history, lifetime weight, binge eating and methods of weight loss/control, and menstrual cycle history as well as eating pattern for the past 12 months, (3) a comprehensive assessment using structured and semistructured psychiatric interviews conducted by phone or in person, and (4) a face-to-face interview and physical examination with a psychiatrist. To be considered “recovered,” participants had to (1) maintain a weight above 85% average body weight, (2) have regular menstrual cycles, and (3) have not binged, purged, or engaged in significant restrictive eating patterns for at least 1 year before the study. Restrictive eating patterns were defined as regularly occurring behaviors, such as restricting food intake, restricting high-caloric food, counting calories, and dieting. In addition, participants must not have used psychoactive medication such as antidepressants or met criteria for alcohol or drug abuse or dependence, major depressive disorder, or severe anxiety disorder within 3 months of the study. Normal volunteer women were recruited through local advertisements and did not have any stigmata suggestive of an eating disorder (ED). They had maintained an average body weight between 90% and 120% since menarche, had normal menstrual cycles, and had never binged, purged, or engaged in significant restrictive eating patterns suggestive of an ED. Their lab tests, medical and psychiatric histories, and physical and neurological examinations indicated no current or past psychiatric, medical, or neurological illness.

This study was conducted according to the institutional review board regulations of the University of California, San Diego, and all participants gave written informed consent.

The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I)16 was used to assess the lifetime prevalence of Axis I psychiatric disorders. The eating disorder diagnosis was made by a modified version of module H of the SCID I. Current psychopathology was assessed with a battery of standardized instruments including the Beck Depression Inventory,17 the Spielberger State-Trait Anxiety Inventory,18 the Eating Disorders Inventory,19 the Yale-Brown Obsessive Compulsive Scale,20, 21 the Barratt Impulsiveness Scale,22 and the Temperament and Character Inventory23 for assessment of harm avoidance, novelty seeking, and reward dependence.

DASB Radiochemistry Preparation

[11C]DASB was prepared at the UCSD Center for Molecular Imaging, PET Radiochemistry Laboratory. Radioactive [11C]CO2 was produced by the 14N(p, α)11C nuclear reaction at the CTI RDS 111 cyclotron operated by PETNET. The [11C]CO2 was converted into [11C]CH3I or sequentially swept into a silver triflate oven to produce [11C]methyl triflate. Desmethyl-DASB precursor was reacted using the loop injection port procedure. Then, the contents of the loop were quantitatively injected into a semi-preparative liquid chromatography column. The [11C]DASB fraction was isolated, passed through a 0.22-μm sterile Millex-GV membrane filter, and collected in a 30-ml sterile vial containing 10 ml of 0.9% sterile saline. For [11C]DASB, the radiochemical yield was 18–22% at the end of synthesis. The total synthesis time was 50 ± 5 min. The average specific activity at the end of the analysis averaged 13 ± 2 Ci/μmol. The studies were carried out under IND 74, 254 for [11C]DASB.

Image Acquisition

Participants were scanned at around 1 pm depending on [11C]DASB radiochemistry preparation and were asked to eat their usual breakfast in the morning after they got up. The breakfast was not standardized. Participants were positioned in a Siemens/CTI ECAT HR+ scanner (Siemens Medical Systems, 810 Innovation Dr., Knoxville, TN) with the head oriented such that the lowest imaging plane was approximately 1 cm above and parallel to the cantho-meatal line. A vacuum head holder attached to the PET scanner bed minimized head movement during the scan acquisition. A 20-min transmission scan with integral germanium rods was performed for scatter and attenuation correction before radiopharmaceutical injection. [11C]DASB (10 mCi) was injected and dynamic frame-based emission scanning was initiated: 6 s/frame × 15 frames, 10 s/frame × 3 frames, 30 s/frame × 12 frames, one frame at 120 s, 300 s/frame × 2 frames, 600 s/frame × 7 frames, giving a total of 40 frames and 90 min of imaging. A calibration was performed between the dose calibrator, gamma well counter, and scanner using an F-18 cylinder calibration on the same day of each participant study. After correction with the system normalization file and measured attenuation, the 40 frame dynamic images were reconstructed with the Siemens iterative OS-EM reconstruction software using four iterations and 16 subsets.

Computation of Binding Potential

Logan graphical analysis24 was applied to the [11C]DASB images, and parametric images were generated on a voxel-by-voxel basis using the cerebellar time-activity curve as the input function. The Logan graphical analysis is a technique that allows the estimation of local tissue distribution volumes (VT) of reversibly bound radiopharmaceuticals by generating a plot in which the y-axis consists of ratios of integrated and measured tissue time-activity data and the x-axis typically contains the ratio of integrated plasma activity and measured tissue activity. The slope of this plot represents VT. A modification of the Logan analysis, which incorporates an assumed constant average tissue to plasma clearance of the cerebellum as the reference tissue region, was used.25, 26 The binding potential (BP) was calculated with the formula: BPnondisplaceable (ND) = (VT/VND) −1.24, 27 This assumption was based on the negligible density of 5-HTT in the cerebellum. The cerebellar radioactivity detected on the images was due to free unbound blood pool activity.

The resulting parametric images have cerebellar values of approximately zero (unity) because the hand-drawn regions of interest in the cerebellum (similar to those used elsewhere28) were used as the plasma input function. However, for the convenience of graphics programs, we have not subtracted the “1” in the binding potential equation in order that every numerical value would be positive. Values in 16 regions of the Analysis of Functional Neuroimages (AFNI) cerebellum, which were used for validation only, were close to 0.0 (presented graphically as 1.0) as anticipated from the model used. We recognize that the cerebellum does have some displaceable binding and its regions are not entirely uniform.28 Although some variation was found among the 16 cerebellar regions in the AFNI region of interest, there was no significant group or group by region interaction (F = 0.02, df = 1, 14, p = .96 and F = 0.55, df = 27, 378, p = .97), respectively. We also explored a second method of identifying the cerebellar reference region using independent components analysis to identify and separate the nonspecific and specific binding areas. The input function was extracted from a computational method using factor analysis29, which was modified from a previously described method30 to address the problem that the cerebellum is known to have areas of [11C]DASB binding and non-binding. The nonbinding [11C]DASB time activity curve and associated regions were extracted by applying factor analysis on the entire cerebellum on the dynamic reconstructed image files. This resulted in values that were approximately 5–10% higher for 15 of the 16 participants, with one outlier participant. Without the outlier, this second reference produced values, which correlated 0.90–0.95 with the hand-drawn reference.

Image Analysis

[11C]DASB parametric images had the skull removed with the Brain Extraction Tool (BET), were coregistered, and were standardized to the Montreal Neurological Institute (MNI) brain using the Linear Image Registration Tool (FLIRT) of the Functional Magnetic Resonance Imaging of the Brain [FMRIB] Software Library (FSL).31 Voxel-by-voxel t-tests comparing the two participant groups were computed with AFNI 3dttest using a white matter mask and compared using the Brainflow visualizer (Fig. 1).

thumbnail image

Figure 1.. Mean [11C]DASB VT/VND in REC BN and CW. Top Row: Images of [11C]DASB VT/VND in sagittal section. Left: Mean [11C]DASB VT/VND in eight CW standardized to the MNI anatomical brain; color bar at right edge shows cerebellar values at reference level of approximately 1.0 (1.0 not subtracted). Right: [11C]DASB VT/VND in REC BN on same color scale. Bottom Row: Left: Regions with [11C]DASB VT/VND lower than CW are shown in parasagittal slice (y = −9) located at maximum Z value for largest cluster (#1) in superior cingulate, Brodmann area 23. Cluster numbers correspond to Table 2. Threshold for one-tailed test, t = −1.76, p < .05 is the right edge of the color bar under left sagittal image and levels 0.025, 0.01 are marked. The left edge of the color bar is the p < .005 threshold, and all t values > 2.97 are the color of the left edge. Using this threshold combined with a full p-value color bar (rather than merely a threshold) the reader can either compare the data with our earlier findings, the current ROI MANOVA findings, or our directional hypotheses, or alternately view all analyses as exploratory. Note this is a parasagittal slice so that the medial frontal cortex is present for region 1 (Talairach daemon, see Table 2). Bottom row: Right: Regions with [11C]DASB VT/VND higher than CW. Sagittal slices at x centers of largest clusters. Vertical color bar at right edge of illustration shows one-tailed p-values for both positive and negative values with low threshold light orange p < .05, one-tailed for t > 1.76, df = 14 (marked with black triangle) and high threshold t = 2.97 for p > .005 (marked with red-orange triangle); t-values lower than 1.76 are not presented as colored areas. Each cluster number corresponds to Table 2 entries giving the xyz location of the cluster center, Z maximum value, volume of each voxel cluster, and anatomical area as indicated by Talairach Daemon. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Download figure to PowerPoint

Statistical Analysis

On the basis of earlier studies in eating disorders, t-test maps are presented with a p < .05 threshold for analysis which confirm other previously published results and a color bar extending up to .005 for exploratory analyses where the result has not been published before.

In addition, a region of interest (ROI) analysis was performed. The following ROIs from AFNI were used to match our previously used ROIs10 for the assessment of 5-HTT binding: dorsal raphe, a modification of the “red nucleus” AFNI region, by moving it to the midline and extending it dorsoventrally; anterior ventral striatum, anterior half of the AFNI caudate region; thalamus; dorsal caudate; and subgenual cingulate (Brodmann Area 25/11). Since we have previously reported significant group differences with MANOVA and follow-up ANOVA, we have presented univariate follow-up statistics in replication with one-tailed tests.

Results

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Demographics and Assessments

The REC BN and CW groups did not differ significantly in age, body-mass index (BMI), or assessments (Table 1). Lifetime comorbidity in REC BN included history of major depressive disorder (n = 4), depressive disorder, not otherwise specified (n = 2), obsessive-compulsive disorder (n = 3), alcohol dependence (n = 2), cocaine dependence (n = 1), and any anxiety disorder (n = 3). All eight REC BN had at least one lifetime comorbid psychiatric disorder.

Table 1. Demographic values between groups
 CW (n = 8)REC BN (n = 8)Wilcoxon Rank-Sum Test
MeanSDMeanSDExact Sig.
  • Sig., Significance; CW, healthy control women; BN, bulimia nervosa; BDI, Beck Depression Inventory; TCI, Temperament and Character Inventory; BIS, Barrett Impulsivity Scale; STAI, State Trait Anxiety Inventory; EDI-2, Eating Disorder Inventory-2.

  • a

    Indicates one missing value.

Age (years)27.947.2726.098.090.51
Current BMI (kg/m2)21.631.7722.072.500.72
Low BMI lifetime (kg/m2)19.871.4418.772.000.11
High BMI lifetime (kg/m2)22.401.8623.972.740.23
Age of onset (years of age)16.252.25
Length of recovery (months)51.2554.63
Yale-Brown Obsessive Compulsive Scale (YBOCS) (“current”)002.004.140.23
Novelty seeking (TCI)21.254.3021.36a4.920.87
Harm avoidance (TCI)9.003.127.35a3.070.28
Reward dependence (TCI)16.753.3718.56a3.230.46
Depression (BDI)3.753.651.881.460.44
State anxiety (STAI)28.638.6531.639.930.51
Trait anxiety (STAI)31.757.4830.506.500.65
Motor impulsiveness (BIS)22.383.2023.386.520.96
Attentional impulsiveness (BIS)14.253.7716.005.810.57
Non-planning impulsiveness (BIS)22.003.8521.636.500.65
EDI-2 drive for thinness1.131.734.256.820.44
EDI-2 bulimia1.001.772.57a4.430.69
EDI-2 impulse regulation000.631.190.44

Maps of [11C]DASB VT/VND and Differences between Recovered BN versus CW

[11C]DASB VT/VND values showed highest levels in midbrain regions, consistent with previous reports. Mean values were somewhat lower than individual peak values, reflecting the effects of image averaging. The cingulate appeared to have the highest cortical values. Quantitative images with color bar are shown in Figure 1. REC BN had higher values than CW in superior temporal cortex and anterior cingulate (Fig. 1, Table 2). Lower [11C]DASB VT/VND values were observed in midbrain regions as well as superior and inferior cingulate (Fig. 1, Table 2).

Table 2. Number of voxels, and Z scores for areas of most prominent 5-HTT binding showing differences between REC BN and CW
Number of VoxelsNo. in Figure 1Z ScoreTalairach CoordinatesTalairach Daemon Structure
xyz
  • BA, Brodmann area.

  • a

    Numbers in Figure 1, bottom row, right panel.

  • b

    Numbers in Figure 1, bottom row, left panel

14,2731a4.322411−30Superior temporal gyrus, BA 38,28
1,2192a3.04103816Anterior cingulate gyrus, BA 25
1,2043a3.6512138Anterior cingulate gyrus, BA 24
9,8841b5.04−18−19−29Superior cingulate, BA 23
3,5332b3.56−7−32−23Midbrain
1,5583b3.59−524−6Inferior cingulate, BA 32

Region of Interest Analysis

An overall MANOVA showed a significant group by region difference (F = 8.41 df = 4,11 p = .0023; Wilks' lambda = 0.246) (Table 3), with REC BN showing lower [11C]DASB BPND in the dorsal raphe at a level approaching significance (p = .07).

Table 3. Regional [11C]DASB BPND between groups
 CW (n = 8)REC BN (n = 8)ANOVA
MeanSDMeanSDUncorrected p Value
  1. CW, healthy control women; REC, recovered; BN, bulimia nervosa; SD, standard deviation.

  2. Overall MANOVA showed a significant group by region difference (see text, F = 8.41 df = 4,11 p = 0.0023; Wilks' lambda = 0.246).

Dorsal raphe0.880.150.710.18.07
Anterior ventral striatum0.510.160.460.08.41
Thalamus0.510.140.450.06.24
Dorsal caudate0.380.120.350.12.44
Subgenual cingulate0.050.070.100.09.24

Discussion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

This study, which is the first to use PET and [11C]DASB in REC BN participants, lends further support to the notion that BN have altered 5-HTT functional activity after recovery. Two methods of analysis were used in this study: a voxel-by-voxel analysis and a ROI-based analysis. The voxel-based analysis showed that REC BN had significantly diminished 5-HTT measures in the midbrain, most likely involving the dorsal raphe, which contains the cell bodies of serotonin neurons. Importantly, the voxel-by-voxel-based data also showed that REC BN have diminished [11C]DASB binding in the superior and inferior cingulate, as well as increased binding in the superior temporal cortex and anterior cingulate (subgenual cingulate). These preliminary data reflecting increased and decreased binding will require confirmation in future larger scale studies. Subgenual cingulate and mesial temporal regions are part of the ventral limbic system and thus play a pivotal role in modulating emotionality and integration of cognition and mood. It is possible that aberrant function of these circuits2 might contribute to extremes of behavioral disinhibition, disorganization, and loss of self-control in BN.

The “a priori” choice of regions for the ROI analysis in this study was based on two factors. First, 5-HTT has a large range of region-specific functional activity throughout the brain. Thus, for the ROI-based analysis, we have chosen ROIs with moderate to high binding,13 including the midbrain (dorsal raphe), striatum (anterior ventral striatum and dorsal caudate), thalamus, and subgenual cingulate. Second, these ROIs were previously selected for the assessment of 5-HTT binding in REC EDs in our [11C]McN5652 study.10 That study used a ROI-based analysis with [11C]McN565210 and showed that nine REC BN had a nonsignificantly lower midbrain (dorsal raphe) binding compared to 10 CW (t = 0.90, p = ns, effect size (group difference/group SD) = 0.41).

Because of limited funding, we were only able to study eight REC BN and eight CW with [11C]DASB. Although the MANOVA ROI analysis showed a significant group by region difference, post-hoc individual ROI analysis showed a group difference in the dorsal raphe which approached significance (p = .07, uncorrected). PET studies with radioligands are an expensive and difficult technology. Consequently, studies to date in REC BN participants have been underpowered. Still, these data support the need for larger scale studies that are adequately powered to confirm these findings.

A better understanding of altered 5-HTT function may have important clinical relevance for BN. First, selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are commonly used in BN. However, many individuals have partial to poor response, or response diminishes over time.32 Second, 5-HTT function has been associated with extremes of impulse control in BN.1, 33 The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity. [11C]DASB is not displaced from 5-HTT sites by physiologically relevant serotonin concentrations.34, 35 One model35 proposes a clearance effect of 5-HTT, with less functioning 5-HTT associated with greater extracellular 5-HT.35, 36 This is consistent with our studies' findings of elevated cerebrospinal fluid measures of the major metabolite of 5-HT, 5-hydroxyindoleacetic acid.6 One possibility, although conjectural, is that those individuals with reduced 5-HTT binding may have increased extracellular 5-HT, which in turn will result in altered 5-HT receptor activation, and thus may contribute to behavioral symptoms. It is worth noting that REC BN individuals tend to have higher binding of 5-HT1A postsynaptic receptors and autoreceptors.37 The cause and effect relationship between altered 5-HT1A and 5-HTT function in REC BN remains to be determined. Still, these data raise questions as to whether individuals with aberrant 5-HTT function may respond differently to SSRIs, or may be prone to dysregulated impulse control. Such insights may allow for the development of new strategies that could result in improved treatments.

This small-scale study suggests that [11C]DASB.12 is superior to [11C]McN5652 in terms of revealing differences of 5-HTT binding between REC BN and CW. Because of its higher specific-to-nonspecific binding ratios, [11C]DASB showed binding differences in regions, such as cingulate and temporal cortices, that were not found with [11C]McN5652. However, this study has certain limitations. For instance, we were only able to compare the ROI based analysis between the current and the previous study, as we did not perform a voxel-by-voxel analysis in the [11C]McN5652 study.10 In addition, our dorsal raphe assessment was based on the MNI brain, and not hand drawn. Therefore, variations in the exact position of the raphe, as well as the other assessed ROIs, may have created random error, which limited our power to detect further differences in the ROI-based analysis. Moreover, though persistent alterations in monoamine activity after recovery raise the question of whether this is a premorbid vulnerability for developing ED symptoms, it is also possible that chronic disturbances of nutrition during the ill state might contribute to a persistent “scar,” caused by chronic malnutrition, in recovered individuals. Patients were off medication (e.g., SSRIs) for greater than 3 months, so it is unlikely that persistent effects of 5-HT active medication accounted for the results. Lastly, our findings are limited by the variable of seasonality, as demonstrated previously38–40 To evaluate this, we grouped individual scans for each diagnostic group (REC BN, CW) according to season of scan with the equinoxes as the cut-off between the fall and winter season and the spring and summer season: for fall and winter, the scan dates were September 22 to March 20 (1 CW, 3 REC BN), and for spring and summer, the scan dates were March 21 to September 21 (7 CW, 5 REC BN). Thus, we have a too small sample to carry out statistical analysis. However, we note that Kalbitzer et al.39 showed no seasonal effect for the midbrain, our area of strongest finding. Praschak-Rieder et al.38 found higher binding in fall and winter, but since the majority of both our CW and REC BN were studied in summer it would be difficult to attribute our results entirely to seasonal bias.

The findings of this study support the hypothesis of altered 5-HTT binding in individuals recovered from BN, specifically in the midbrain and temporal and cingulate cortices. Although the necessity for larger scale studies remains, insight gained from this and previous studies may prove invaluable to our improved understanding of BN and to the development of superior pharmacological treatment strategies for the disease.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Dr. Kaye has received salary support from the University of Pittsburgh and the University of California, San Diego; Research funding/support from the NIMH; Research funding for an investigator initiated treatment study from Astra-Zeneca and consulting fees from Lundbeck and Merck and the Eating Disorder Center of Denver. In addition, there are honoraria for presentations from academic institutions and meetings, and compensation for grant review activities from the National Institutes of Health. Dr. Bailer has received salary support from the Hilda & Preston Davis Foundation and the Price Foundation.

Drs. M. S. Buchsbaum, C.K. Hoh, R. Pichika, B.R. Buchsbaum, and A. de Castro received no specific financial support for this work of any kind other than institutional salary and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

Earn CE credit for this article!

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References

Visit: http://www.ce-credit.com for additional information. There may be a delay in the posting of the article, so continue to check back and look for the section on Eating Disorders. Additional information about the program is available at www.aedweb.org

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Method
  5. Results
  6. Discussion
  7. Acknowledgements
  8. Earn CE credit for this article!
  9. References
  • 1
    Engel SG,Corneliussen SJ,Wonderlich SA,Crosby RD,le Grange D,Crow S, et al. Impulsivity and compulsivity in bulimia nervosa. Int J Eat Disord 2005; 38: 244251.
  • 2
    Kaye WH,Fudge JL,Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nature Rev 2009; 10: 573584.
  • 3
    Morgan JC,Wolfe BE,Metzger ED,Jimerson DC. Obsessive-compulsive characteristics in women who have recovered from bulimia nervosa. Int J Eat Disord 2007; 40: 381385.
  • 4
    Kaye W,Strober M,Stein D,Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry 1999; 45: 12851292.
  • 5
    Kaye WH,Frank GK,Meltzer CC,Price JC,McConaha CW,Crossan PJ, et al. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 2001; 158: 11521155.
  • 6
    Kaye WH,Greeno CG,Moss H,Fernstrom J,Fernstrom M,Lilenfeld LR, et al. Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch Gen Psychiatry 1998; 55: 927935.
  • 7
    Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215235.
  • 8
    Tauscher J,Pirker W,Willeit M,de Zwaan M,Bailer U,Neumeister A, et al. [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry 2001; 49: 326332.
  • 9
    Kuikka JT,Tammela L,Karhunen L,Rissanen A,Bergstrom KA,Naukkarinen H, et al. Reduced serotonin transporter binding in binge eating women. Psychopharmacology 2001; 155: 310314.
  • 10
    Bailer UF,Frank GK,Henry SE,Price JC,Meltzer CC,Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007; 195: 315324.
  • 11
    Steiger H,Richardson J,Israel M,Ng Ying Kin NM,Bruce K,Mansour S, et al. Reduced density of platelet-binding sites for [3H]paroxetine in remitted bulimic women. Neuropsychopharmacology 2005; 30: 10281032.
  • 12
    Frankle WG,Huang Y,Hwang DR,Talbot PS,Slifstein M,Van Heertum R, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nuclear Med 2004; 45: 682694.
  • 13
    Frankle WG,Slifstein M,Gunn RN,Huang Y,Hwang DR,Darr EA, et al. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: Reproducibility and comparison of methods. J Nuclear Med 2006; 47: 815826.
  • 14
    Bailer UF,Frank GK,Henry SE,Price JC,Meltzer CC,Weissfeld L, et al. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry 2005; 62: 10321041.
  • 15
    Wagner A,Greer P,Bailer UF,Frank GK,Henry SE,Putnam K, et al. Normal brain tissue volumes after long-term recovery in anorexia and bulimia nervosa. Biol Psychiatry 2006; 59: 291293.
  • 16
    First M,Spitzer R,Gibbon M,Williams J. Structured Clinical Interview for Axis I Disorders-Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute, 1996.
  • 17
    Beck A,Ward C,Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961; 3: 461471.
  • 18
    Spielberger C,Gorsuch R,Lushene R,Vagg P,Jacobs G. Manual for the State-Trait Anxiety Inventory (STAIForm Y). Palo Alto, CA: Consulting Psychologists Press, 1983.
  • 19
    Garner D. The Eating Disorders Inventory-2 Manual. Odessa, FL: Psychological Assessment Resources, 1991.
  • 20
    Goodman WK,Price LH,Rasmussen SA,Mazure C,Fleischmann RL,Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 10061011.
  • 21
    Goodman WK,Price LH,Rasmussen SA,Mazure C,Delgado P,Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46: 10121016.
  • 22
    Barratt ES. The biological basis of impulsiveness: The significance of timing and rhythm. Personality Individual Diff 1983; 4: 387391.
  • 23
    Cloninger C,Przybeck T,Svrakic DRW. The temperament and character inventory (TCI): A guide to its development and use. St. Louis: Center for Psychology of Personality, Washington University, 1994.
  • 24
    Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nuclear Med Biol 2003; 30: 833844.
  • 25
    Ginovart N,Wilson AA,Meyer JH,Hussey D,Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab 2001; 21: 13421353.
  • 26
    Logan J,Fowler JS,Volkow ND,Wang GJ,Ding YS,Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834840.
  • 27
    Innis RB,Cunningham VJ,Delforge J,Fujita M,Gjedde A,Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 15331539.
  • 28
    Parsey RV,Kent JM,Oquendo MA,Richards MC,Pratap M,Cooper TB, et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 2006; 59: 821828.
  • 29
    Hoh C. Independent component analysis minimizing the mutual information criteria in polar coordinates. Presented at International Multi-conference on Complexity, Informatics, and Cybernetics, Orlando, Florida, 2010.
  • 30
    Wu HM,Hoh CK,Choi Y,Schelbert HR,Hawkins RA,Phelps ME, et al. Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nuclear Med 1995; 36: 17141722.
  • 31
    Jenkinson M,Bannister P,Brady M,Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17: 825841.
  • 32
    Walsh BT. Psychopharmacologic treatment of bulimia nervosa. J Clin Psychiatry 1991; 52 ( Suppl): 3438.
  • 33
    Steiger H,Joober R,Israel M,Young SN,Ng Ying Kin NM,Gauvin L, et al. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes. Int J Eat Disord 2005; 37: 5760.
  • 34
    Cannon DM,Ichise M,Rollis D,Klaver JM,Gandhi SK,Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007; 62: 870877.
  • 35
    Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86102.
  • 36
    Yamamoto S,Onoe H,Tsukada H,Watanabe Y. Effects of increased endogenous serotonin on the in vivo binding of [11C]DASB to serotonin transporters in conscious monkey brain. Synapse 2007; 61: 724731.
  • 37
    Bailer U,Bloss CS,Frank GK,Price JC,Meltzer CC,Mathis C, et al. 5-HT1A Receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. Int J Eating Disord, 2010 Sept. 24; [Epub ahead of print (DOI: 10.1002/eat.20843)].
  • 38
    Praschak-Rieder N,Willeit M,Wilson AA,Houle S,Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65: 10721078.
  • 39
    Kalbitzer J,Erritzoe D,Holst KK,Nielsen FA,Marner L,Lehel S, et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 2010; 67: 10331039.
  • 40
    Ruhe HG,Booij J,Reitsma JB,Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: Effect of season and gender. Eur J Nucl Med Mol Imaging 2009; 36: 841849.